78 results
Page 3 of 4
8-K
EX-99.1
5y2ukk ztj1mxe5oo2
13 Apr 20
ENDRA Life Sciences Announces Cash Strategy and Business Update in Response to COVID-19
4:29pm
8-K
EX-1.1
cdvjru4y2b62a zi6sw
27 Mar 20
Entry into a Material Definitive Agreement
5:19pm
424B5
z9eecibf
27 Mar 20
Prospectus supplement for primary offering
5:19pm
8-K
EX-99.1
0dg8l2a494xzbr95
10 Mar 20
ENDRA Life Sciences Receives CE Mark for its TAEUS® Clinical Product Targeting Non-Alcoholic Fatty Liver Disease
8:02am
424B3
hdx9a07 jjevefqvvto
28 Jan 20
Prospectus supplement
4:59pm
8-K
EX-10.1
0jou331eby
26 Dec 19
Entry into a Material Definitive Agreement
4:15pm
8-K
EX-10.1
9t979f220g
11 Dec 19
ENDRA Life Sciences Completes $8.1 Million Private Placement
5:14pm
424B7
y3k3n08hn5bwwz4w
16 Sep 19
Prospectus with selling stockholder info
4:10pm
8-K
EX-10.1
ro0nyr2w hvek
29 Jul 19
ENDRA Life Sciences Completes Private Placement of $2.8 Million of Convertible Secured Notes and Warrants
8:40am
424B3
ytlhtzb1 h257qcakx
12 Feb 19
Prospectus supplement
12:00am